- Home
- SVA vs CADL Comparison
SVA vs CADL Comparison
Compare SVA & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVA
- CADL
- Stock Information
- Founded
- SVA N/A
- CADL 1999
- Country
- SVA
- CADL United States
- Employees
- SVA 3261
- CADL N/A
- Industry
- SVA
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- SVA
- CADL Health Care
- Exchange
- SVA NYSE
- CADL Nasdaq
- Market Cap
- SVA N/A
- CADL 252.0M
- IPO Year
- SVA N/A
- CADL 2021
- Fundamental
- Price
- SVA $6.47
- CADL $5.81
- Analyst Decision
- SVA
- CADL Strong Buy
- Analyst Count
- SVA 0
- CADL 5
- Target Price
- SVA N/A
- CADL $21.40
- AVG Volume (30 Days)
- SVA N/A
- CADL 1.0M
- Earning Date
- SVA N/A
- CADL 08-12-2025
- Dividend Yield
- SVA N/A
- CADL N/A
- EPS Growth
- SVA N/A
- CADL N/A
- EPS
- SVA N/A
- CADL N/A
- Revenue
- SVA N/A
- CADL N/A
- Revenue This Year
- SVA N/A
- CADL N/A
- Revenue Next Year
- SVA N/A
- CADL N/A
- P/E Ratio
- SVA N/A
- CADL N/A
- Revenue Growth
- SVA N/A
- CADL N/A
- 52 Week Low
- SVA N/A
- CADL $3.79
- 52 Week High
- SVA N/A
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- SVA N/A
- CADL 58.86
- Support Level
- SVA N/A
- CADL $4.86
- Resistance Level
- SVA N/A
- CADL $6.42
- Average True Range (ATR)
- SVA 0.00
- CADL 0.34
- MACD
- SVA 0.00
- CADL 0.13
- Stochastic Oscillator
- SVA 0.00
- CADL 68.56
About SVA SINOVAC BIOTECH LTD
Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.